Segmental infantile hemangiomas (IH) can be associated with congenital anomalies in a regional distribution. PHACE refers to large cervicofacial segmental IH in association with congenital anomalies of the aortic arch and medium-sized arteries of the head and neck, as well as structural anomalies of the posterior fossa and eye. A subset of PHACE patients have arterial anomalies that progress to moyamoya vasculopathy (MMV). MMV is defined as stenosis of the supraclinoid segment of the internal carotid arteries and/or their major branches, with subsequent development of a compensatory collateral vessel network. We describe a patient with MMV and segmental IH on the back and lower body who meets diagnostic criteria for PHACE based on a posterior segment eye anomaly and cerebral arterial anomalies. Whole exome sequencing demonstrated two inherited heterozygous variants in RNF213. Variants in RNF213 are associated with increased susceptibility to MMV. Our findings suggest that RNF213
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hemangiomas, arterial anomalies, cardiac defects, and eye abnormalities characteristic of the disease (Frieden, Reese, & Cohen, 1996) .
Midline ventral defects such as sternal clefting or supraumbilical raphe can also be present. A subset of patients with PHACE have segmental IH on the upper body, rather than the face, in association with arch anomalies, structural brain, or cervical and cerebral arterial anomalies. This was initially described as "PHACE without face" (Nabatian et al., 2011) . More recently, the diagnostic criteria for definite or possible PHACE have been expanded to include patients with segmental IH on the trunk, or even lacking a hemangioma (Garzon et al., 2016) .
Head and neck arterial anomalies are the most common extracutaneous findings in PHACE, affecting 91% of patients, and can include complete absence, dysplasia, narrowing, aberrant course or origin, and persistence of fetal-pattern vasculature (Haggstrom et al., 2010) . Rarely the cervical and cerebrovascular anomalies observed in PHACE are progressive, leading to moyamoya vasculopathy. Moyamoya vasculopathy is defined as stenosis or occlusion of the internal carotid arteries or their distal branches with subsequent development of a compensatory network of fine collateral vessels, occurring in patients with another underlying disorder (Fujimura & Tominaga, 2015) . MMV is variably referred to as "quasi-moyamoya disease," "moyamoya syndrome," or "secondary moyamoya disease" to distinguish this phenomenon from idiopathic moyamoya disease (MMD) (Fujimura & Tominaga, All reported PHACE patients with MMV have associated congenital anomalies of cervical and/or cerebral arteries, but not all PHACE patients with congenital arterial anomalies will develop MMV.
In fact, MMV is a relatively uncommon finding in PHACE, affecting fewer than 7% of patients (Heyer et al., 2008) . However, because the population of known PHACE patients is young, and MMV develops progressively, the incidence of MMV in PHACE may be underestimated. Importantly, severe cerebral and/or cervical arterial anomalies, especially if progressive with the development of MMV, confer an increased risk for stroke in PHACE (Siegel et al., 2012) . It is unknown why a particular subset of individuals with PHACE develops this MMV phenotype.
RNF213 has been identified as a susceptibility gene for MMD (Kamada et al., 2011) . The RNF213 founder variant p.R4810K has been strongly associated with both MMD and MMV in patients of Asian descent (Liu, Hitomi, Kobayashi, Harada, & Koizumi, 2012; Morimoto et al., 2016) . However, additional rare RNF213 variants have also been described in non-Asian MMD patients (Cecchi et al., 2014) . Of note, the vast majority of variants associated with MMD identified to date are missense variants, suggesting that more significant alteration of the gene may not be tolerated. In this report, we describe two compound heterozygous RNF213 variants in association with MMV in a patient with PHACE. To our knowledge, this is the first report of RNF213 variants in a hemangioma syndrome.
| CLINICAL REPORT
The patient is a female of Caucasian and African-American descent who presented to dermatology clinic at 5 years old for evaluation for PHACE. She had a history of a large segmental infantile hemangioma located on the sacral back extending to the right posterior thigh and ankle. Magnetic resonance imaging (MRI) of the lower spine was unremarkable. Treatment of the infantile hemangioma during the 1st year of life included oral corticosteroids and pulsed-dye laser therapy.
She had a history of decreased visual acuity in the left eye (20/800). She had normal development and no neurologic symptoms until age 4 years, when she began to have episodes of vomiting. By age 5 years, she was able to articulate that the episodes of vomiting were associated with headaches. She had no seizures and an electroencephalogram was normal. There is no family history of epilepsy or early strokes.
Physical examination was notable for a faint, telangiectatic patch on the lower back over the sacrum, extending to the buttocks and right popliteal fossa. There was no vascular stain or hemangioma on the face or scalp.
There were no skeletal abnormalities, and neurologic exam was normal. were extracted using standard protocols. Whole exome sequencing data were generated on the Illumina HiSeq 2000 platform (Illumina, Inc; San Diego, CA). Overall mean depth of coverage was 81X in tissue and 103X in blood. The mean depth of coverage for RNF213 (NM_001256071) was 83X in tissue and 106X in blood. Variants were called via the Genome Analysis Toolkit best practices methods (GATK, Broad Institute). Variants were analyzed using an in-house developed application called CarpeNovo (Worthey et al., 2011) . In silico modeling was performed using domain and protein ordered/ disordered prediction tools and was modeled using the I-TASSER suite of protein modeling tools. The model was inserted into an aqueous environment with a pH of 7.4, energy minimized using YASARA and molecular dynamic simulations performed using AMBER03. Variants were confirmed with orthogonal Sanger-based clinical grade sequencing at the Children's Hospital of Wisconsin (Figure 2 ).
| RESULTS
Whole exome sequencing analysis of the proband samples revealed compound heterozygous variants in RNF213 (Figure 2 (Figure 3b) , however the p.Q469H protein change is predicted to be possibly damaging by changing the protein domain dynamics with in silico modeling (Figure 3c ). The p.W4677L variant was predicted to be "possibly damaging" by PolyPhen (PolyPhen-2 HumVar score = 0.879) and "damaging" by SIFT (SIFT score = 0.000), while the p.Q469H variant was predicted to be "possibly damaging" by Polyphen (0.533) and "tolerated" by SIFT (0.112).
Whole exome sequencing was performed on 27 additional blood samples from PHACE patients, six of whom had MMV. The p.W4677L variant seen in the proband was present in one other patient; the p.
Q469H variant was not present in any. WES of additional samples and validation of variants is ongoing.
| DISCUSSION
Large segmental IH on the head and neck are most commonly associated with cervical and cerebral arterial anomalies, structural brain anomalies, and congenital heart defects in PHACE. When located on the lower body, segmental hemangiomas can be associated with developmental anomalies described by the acronym LUMBAR (Lower body hemangiomas, Urogenital anomalies, Ulceration, Myelopathy, Bone deformities, Anorectal/Arterial malformations, Renal anomalies) (Iacobas et al., 2010) . Less commonly, lower body hemangiomas co-occur with anomalies typical of PHACE. In this report we describe a patient with lower back and extremity segmental IH in association with staphyloma, an ocular structural anomaly associated with PHACE, as well as the classic arterial anomalies described in PHACE. This constellation of findings meets diagnostic criteria for definite PHACE according to recently updated diagnostic guidelines (Garzon et al., 2016) .
This report highlights the association of MMV with compound heterozygous inherited rare variants within RNF213 in a patient with PHACE syndrome and MMV. The p.W4677L variant observed in our patient was recently associated with MMD in a Caucasian patient from a cohort from the Czech Republic and Slovakia ).
This variant is located at the C-terminal end of the protein within a region of unknown function that contains the Japanese founder variant p.R4810K, as well as other variants previously associated with MMV (Kamada et al., 2011; Miyatake et al., 2012) . The second variant p.Q469H occurs closer to the N-terminus, and is predicted to fall into the potassium dependent sodium calcium exchanger domain, potentially affecting the activity of the protein (Miyatake et al., 2012) .
The severity of the MMV seen in this patient may be explained by the compound heterozygous inheritance of these two potentially damaging variants. In a study of Japanese MMD patients, homozygous individuals had an earlier onset and more severe presentation (Miyatake et al., 2012) .
Moyamoya disease has a reported female preponderance, an observation that has also been made in PHACE. Thus it is possible that disease severity is related to a combination of the number and type of variants present, as well as other modifiers affected by gender or genetic/ environmental factors (Nanba et al., 2006; Miyatake et al., 2012) .
With this report, we have identified RNF213 as a potential modifier of phenotypic features seen in PHACE. Further study of a larger cohort of individuals with PHACE and LUMBAR, especially those with intracranial arterial anomalies and MMV, is needed to further elucidate the frequency and importance of RNF213 in these hemangioma syndromes.
